Rate and predictors of progression in elite and viremic HIV-1 controllers
Agathe León(Hospital Clínic de Barcelona), Felipe García(Apple (Israel)), Carmen Rodríguez(American Cancer Society), Norma Rallón, José M. Benito(Hospital Universitario Rey Juan Carlos), José Alcamı́(Apple (Israel)), Eulàlia Grau(Apple (Israel)), Ignacio Pérez(Apple (Israel)), Cecilio López‐Galíndez(Apple (Israel)), Pompeyo Viciana(Apple (Israel)), José María Gatell(Apple (Israel)), Jose Iribarren(Apple (Israel)), Ezequiel Ruíz-Mateos(Apple (Israel)), José López-Aldeguer(Apple (Israel)), Manuel Leal(Apple (Israel))
Cited by 84
Related Papers
Methods for Pooling Results of Epidemiologic Studies
|American Journal of Epidemiology|2006|330
Ultraviolet vision in lizards
|Nature|1993|257
Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection
|AIDS|2004|115
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
|Journal of Clinical Investigation|2021|110